10/16/2020 9:50 AM
Clarín.com
Society
Updated 10/16/2020 9:50 AM
The antiviral drug remdesivir has a
very small effect in reducing the mortality
of patients with covid-19 and does not seem to help them recover quickly, according to a study by the World Health Organization (WHO) quoted this Friday by the British newspaper
The Financial Times .
"In the results of the highly anticipated WHO Solidarity study, which looked at the effects of remdesivir and three other potential drug treatments in 11,266 hospitalized patients, it found that
none of the treatments substantially affected mortality
or the need to ventilate patients." , indicates
The Financial Times.
Remdesivir is one of several drugs reviewed by this large study of more than 11,000 people in 30 countries, including Argentina.
The antiviral, one of the first to be used as a treatment for covid-19, was one of the drugs used to treat the coronavirus infection of the president of the United States, Donald Trump.
Remdesivir has very little effect in reducing the mortality of coronavirus patients.
Photo Reuter.
"Both remdesivir and hydroxychloroquine, interferon and lopinavir seem to have
little effect on hospital mortality
", details the British media.
As published by the WHO on its website, the Solidarity study "is an international clinical trial to find an effective treatment against covid-19."
The study compares treatment options with the standard of care to evaluate the relative efficacy of each of them against coronavirus.
"The purpose of the Solidaridad study is to quickly discover if any of the drugs studied slow the progression of the disease or
improve the survival rate,
" the WHO highlights.
The data, which
have not yet been reviewed by other physicians
before being published in a scientific journal, appear to contradict at least two large US studies that showed that remdesivir could reduce the length of hospitalizations for patients with COVID-19.
The United States
authorized
the use of the drug on May 1, manufactured by the US pharmaceutical company Gilead Sciences and originally intended to treat Ebola.
The European Union and some countries later authorized it.
Sources: Télam and AFP.
News in development.
LGP
Look also
After Donald Trump's praise for his treatment for the coronavirus, the manufacturer asks for an emergency authorization
China asks WHO to make its coronavirus vaccines available for international use
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/6FPNPGUDHVEQXKMFEHIKH5A6IY.jpg)
